MID ATLANTIC PROSTATE CANCER BANK

前列腺癌是我们这个时代最大的医学挑战之一。它在绝对发病率方面排名第一，仅次于肺癌，是美国男性癌症死亡率的第二大原因。直肠指检和血清前列腺特异性抗原筛查（PSA）的日益普及扩大了公众对前列腺癌的认识、诊断和接受前列腺癌治疗的男性人数。这是在分子病理学的进步为研究人员提供了癌症研究的机会的时候。然而，加强前列腺癌研究的关键是这种恶性肿瘤及其相应的良性和正常对应物的标本的现成可用性。该提案的主要目标是开发一个全面的、用户友好的、最先进的数据库，其中包含最佳保存的前列腺癌、上皮内前列腺肿瘤、良性和正常前列腺组织以及生物（血液、尿液等）标本。标本及其相应的临床数据，以协助将基础研究转化为临床应用。具体目标是：建立一个中大西洋前列腺癌银行（MAPCB），由有能力和有兴趣共同努力实现NCI合作前列腺癌组织资源的创建和目标的机构组成（资源）;建立和维持一个全面的癌症、良性和正常前列腺的高质量固定和冷冻标本以及其他相关细胞和液体标本库，并附有相关的临床数据;建立质量保证系统，以监测收集和保存过程，并确保收集和分发给个别研究人员的材料的质量;建立行政结构，以维护患者的机密性，同时向研究人员提供有关标本和相应临床数据的准确信息;审查有关前列腺癌的新兴研究，以保持库存标本的相关性;与NCI和其他获奖者合作，宣传资源，优化（和标准化）标本和临床数据收集，保存，质量控制和分配流程和政策。这一资源将确保研究人员将获得最佳的研究标本与临床病理相关性，为他们的研究。

Prostate cancer is one of the great medical challenges of our time. It stands first in absolute incidence and second only to lung cancer as a cause of cancer mortality among men in the United States. The increasingly routine use of digital rectal examination and serum prostate-specific antigen screening (PSA) has magnified public awareness, diagnosis, and the number of men undergoing treatment for prostate cancer. This comes at a time when advances in molecular pathology provide researchers expanding opportunities for the study of cancer. However, critical to enhancing research on prostate cancer is the ready availability of specimens of this malignancy and its corresponding benign and normal counterparts. The principal goal of this proposal is to develop a comprehensive, user- friendly, state-of-the-art bank containing optimally preserved specimens of prostate cancer, intraepithelial prostate neoplasms, and benign and normal prostate tissues and biological (blood, urine, etc.) specimens plus their corresponding clinical data in order to assist in the translation of basic research into clinical applications. The specific aims are to: establish a Mid- Atlantic Prostate Cancer Bank (MAPCB) comprised of institutions capable of and interested in working together toward the creation and goals of the NCI Cooperative Prostate Cancer Tissue Resource (Resource); establish and maintain a comprehensive bank of quality fixed and frozen specimens of cancerous, benign and normal prostate and other relevant cell and fluid specimens accompanied by pertinent clinical data; establish a quality assurance system to monitor the collection and preservation processes and ensure the quality of the material collected and distributed to individual investigators; establish an administrative structure to maintain patients' confidentiality while providing investigators accurate information regarding specimens and corresponding clinical data; review emerging research regarding prostate cancer to maintain relevance of banked specimens; and collaborate with the NCI and other awardees to publicize the Resource, optimize (and standardize) specimen and clinical data collection, preservation, quality control, and distribution processes and policies. This resource will assure that investigators will obtain optimal research specimens with clinical-pathologic correlation for their studies.